The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants

Youri Lee(Georgia State University), Eunju Ko(National Institutes of Health), Ki-Hye Kim(Georgia State University), Young‐Tae Lee(Georgia State University), Hye Suk Hwang(Georgia State University), Yu‐Jin Jung(Georgia State University), Subbiah Jeeva(Georgia State University), Young-Man Kwon(Georgia State University), Baik Lin Seong(Yonsei University), Sang‐Moo Kang(Georgia State University)
Antiviral Research
May 28, 2019
10.1016/j.antiviral.2019.05.011
Cited by 2Open Access
Full Text

Abstract

Related Papers

TRAM is specifically involved in the Toll-like receptor 4–mediated MyD88-independent signaling pathway
Masahiro Yamamoto, Shintaro Sato, Hiroaki Hemmi et al.|Nature Immunology|2003|1k
Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes
Jason S. McLellan, Yongping Yang, Barney S. Graham et al.|Journal of Virology|2011|427
Vaccines for the twenty-first century society
Rino Rappuoli, Christian W. Mandl, Steve Black et al.|Nature reviews. Immunology|2011|385
Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10
Mark Connors, Nathalia A. Giese, Arun B. Kulkarni et al.|Journal of Virology|1994|349
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus
Gregory A. Prince, A. Bennett Jenson, V G Hemming et al.|Journal of Virology|1986|311